NS-065/NCNP-01 (Viltolarsen) - Emerging Insight and Market Forecast - 2030

Publisher Name :
Date: 06-Aug-2020
No. of pages: 80
Delivery of the Report will take 2-3 working days once order is placed.

Overview

"NS-065/NCNP-01 (Viltolarsen) - Emerging Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the NS-065/NCNP-01 (Viltolarsen) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Viltolarsen (NS-065/NCNP-01) is an experimental therapy that NS Pharma is developing, with its parent company Nippon Shinyaku, to treat Duchenne muscular dystrophy (DMD) resulting from mutations amenable to exon 53 skipping. It is an infusion that doctors administer into the bloodstream. NS Pharma announced in February 2020 that the U.S. Food and Drug Administration (FDA) accepted its request (called a new drug application or NDA) to review viltolarsen for possible approval. An FDA decision is anticipated in late summer or early autumn 2020. Viltolarsen contains an artificial piece of mRNA that masks exon 53, causing cells to "skip" this exon when they are making mature mRNA. This skip restores the so-called "reading frame" of the mRNA molecule. In other words, it ensures that the remaining exons fit together again, allowing a cell's protein-making machinery to synthesize a shorter but working dystrophin protein. Because viltolarsen is specific to exon 53, the treatment is effective only in those DMD patients who have a mutation that is amenable to exon 53 skipping. A Phase 3 study is actively recruiting. A Phase 2 study completed enrollment and dosing at clinical sites in North America (United States and Canada). All participants elected to enroll into an extension study. All participants continue to be dosed. On February 10, 2020, NS Pharma announced that the FDA has filed a New Drug Application (NDA) for their antisense oligonucleotide drug NS-065/NCNP-01 (viltolarsen). NS Pharma, Inc. shared an update with the community responding to questions about how COVID-19 may be affecting ongoing studies of viltolarsen, the recently launched Expanded Access Program (EAP) and review of the viltolarsen New Drug Application (NDA) by the FDA.

Scope of the report

The report provides insights into:

- A comprehensive product Overview

including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

- Elaborated details on regulatory milestones and other development activities have been provided in this report.

- The report also highlights the drug marketed details across the United States, Europe and Japan.

- The report also covers the patents information with expiry timeline around NS-065/NCNP-01 (Viltolarsen).

- The report contains historical and forecasted sales for NS-065/NCNP-01 (Viltolarsen) till 2030.

- Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

- The report also features the SWOT analysis with analyst insights and key findings of NS-065/NCNP-01 (Viltolarsen).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NS-065/NCNP-01 (Viltolarsen) Analytical Perspective by DelveInsight

- In-depth NS-065/NCNP-01 (Viltolarsen) Market Assessment

This report provides a detailed market assessment of NS-065/NCNP-01 (Viltolarsen) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

- NS-065/NCNP-01 (Viltolarsen) Clinical Assessment

The report provides the clinical trials information of NS-065/NCNP-01 (Viltolarsen) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

- In the coming years, the market scenario for NS-065/NCNP-01 (Viltolarsen) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

- The companies and academics are working to assess challenges and seek opportunities that could influence NS-065/NCNP-01 (Viltolarsen) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

- Other approved products for the disease are giving market competition to NS-065/NCNP-01 (Viltolarsen) and launch of late-stage emerging therapies in the near future will significantly impact the market.

- A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of NS-065/NCNP-01 (Viltolarsen).

- Our in-depth analysis of the sales data of NS-065/NCNP-01 (Viltolarsen) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NS-065/NCNP-01 (Viltolarsen) in the market.

Key Questions

- What is the prescribed dosage and strengths of NS-065/NCNP-01 (Viltolarsen) are available in the market?

- What are the common adverse reactions or side effects of NS-065/NCNP-01 (Viltolarsen)?

- What is the product type, route of administration and mechanism of action of NS-065/NCNP-01 (Viltolarsen)?

- What are the chemical specifications of NS-065/NCNP-01 (Viltolarsen)?

- How are the clinical trials diversified on the basis of the trial status?

- What is the history of NS-065/NCNP-01 (Viltolarsen), and what is its future?

- What are the marketed details of NS-065/NCNP-01 (Viltolarsen) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

- How many patents have been granted to NS-065/NCNP-01 (Viltolarsen) and when these patents will get expire?

- What are the pros (benefits) and cons (disadvantages) of NS-065/NCNP-01 (Viltolarsen)?

- In which countries NS-065/NCNP-01 (Viltolarsen) got approval and when it gets launched?

- What are the clinical trials are currently ongoing for NS-065/NCNP-01 (Viltolarsen)?

- How the safety and efficacy results determined the approval of NS-065/NCNP-01 (Viltolarsen)?

- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NS-065/NCNP-01 (Viltolarsen) development?

- What are the key designations that have been granted to NS-065/NCNP-01 (Viltolarsen)?

- What is the historical and forecasted market scenario of NS-065/NCNP-01 (Viltolarsen)?

- How is the market trend of NS-065/NCNP-01 (Viltolarsen) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?

- What are the other approved products available and how these are giving competition to NS-065/NCNP-01 (Viltolarsen)?

- Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

NS-065/NCNP-01 (Viltolarsen) - Emerging Insight and Market Forecast - 2030

Table of Contents

1. Product Overview
1.1. Indication
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4.1 Dosage Forms and Strengths
1.4. Route of Synthesis
1.5. Pharmacology
1.4.2 Pharmacodynamics
1.4.3 Pharmacokinetics
1.6. Adverse Reactions
1.7. Product Snapshot
1.8. Development Milestones of NS-065/NCNP-01 (Viltolarsen)
1.9. Marketed Details
1.4.4 United States
1.4.5 Europe
1.4.6 Japan
1.10. Patent Details
2. SWOT Analysis
2.1. Analyst Views
3. Regulatory Milestones
3.1. Approvals
3.2. Research and Development
3.3. Clinical Trials Information
3.4. Safety and Efficacy
3.5. Product Developmental Activities
4. Market Assessment
4.1. 7MM Market Analysis
4.2. United States
4.3. Europe
4.4. Japan
4.5. Key Findings
5. Market Competitors
6. Emerging Therapies
7. Appendix
7.1. Report Purchase Options

List of Tables

Table 1 NS-065/NCNP-01 (Viltolarsen), Description
Table 2 NS-065/NCNP-01 (Viltolarsen), Trial Diversification
Table 3 NS-065/NCNP-01 (Viltolarsen), Marketed Details United States
Table 4 NS-065/NCNP-01 (Viltolarsen), Marketed Details Europe
Table 5 NS-065/NCNP-01 (Viltolarsen), Marketed Details Japan
Table 6 Patent Details: NS-065/NCNP-01 (Viltolarsen)
Table 7 NS-065/NCNP-01 (Viltolarsen), Clinical Trial Description, 2020
Table 8 Safety and Efficacy Results for NS-065/NCNP-01 (Viltolarsen)
Table 9 NS-065/NCNP-01 (Viltolarsen), 7MM Market Size from 2017 to 2030 (in Million USD)
Table 10 NS-065/NCNP-01 (Viltolarsen), US Market Size from 2017 to 2030 (in Million USD)
Table 11 NS-065/NCNP-01 (Viltolarsen), EU Market Size from 2017 to 2030 (in Million USD)
Table 12 NS-065/NCNP-01 (Viltolarsen), EU5 Market Size from 2017 to 2030 (in Millions USD)
Table 13 NS-065/NCNP-01 (Viltolarsen), Japan Market Size from 2017 to 2030 (in Million USD)
Table 14 Market Competitors
Table 15 Emerging Therapies

List of Figures

Figure 1 The Development Timeline of NS-065/NCNP-01 (Viltolarsen)
Figure 2 Patent Details, NS-065/NCNP-01 (Viltolarsen)
Figure 3 NS-065/NCNP-01 (Viltolarsen), 7MM Market Size from 2017 to 2030 (in Million USD)
Figure 4 NS-065/NCNP-01 (Viltolarsen), US Market Size from 2017 to 2030 (in Millions USD)
Figure 5 NS-065/NCNP-01 (Viltolarsen), EU Market Size from 2017 to 2030 (in Millions USD)
Figure 6 NS-065/NCNP-01 (Viltolarsen), EU5 Market Size from 2017 to 2030 (in Millions USD)
Figure 7 NS-065/NCNP-01 (Viltolarsen), Japan Market Size from 2017 to 2030 (in Millions USD)
  • Global and United States Sulfachloropyridazine Sodium Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 147
    Sulfachloropyridazine Sodium market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Sulfachloropyridazine Sodium market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Sulfachloropyri......
  • Global and Japan Chitosan Gel Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 141
    Chitosan Gel market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Chitosan Gel market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Chitosan Gel market is segmented into - ......
  • Global and Japan Active Pharma Ingredient Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 171
    Active Pharma Ingredient market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Active Pharma Ingredient market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Active Pharma Ingredien......
  • Global and United States Drug Allergy Treatments and Drugs Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 132
    Drug Allergy Treatments and Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Drug Allergy Treatments and Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Drug ......
  • Global and China Consumer Healthcare Products Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 146
    Consumer Healthcare Products market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Consumer Healthcare Products market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Consumer Health......
  • Global and United States Anti-inflammatory Drugs Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 146
    Anti-inflammatory Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Anti-inflammatory Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Anti-inflammatory Drugs m......
  • Global and Japan Biologic Drugs Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 126
    Biologic Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Biologic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Biologic Drugs market is segmented into......
  • Global and China Glaucoma Treatment Drugs Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 130
    Glaucoma Treatment Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Glaucoma Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Glaucoma Treatment Drug......
  • Global and Japan Rabies Vaccine for Humans Market Insights, Forecast to 2026
    Published: 21-Sep-2020        Price: US 3900 Onwards        Pages: 148
    Rabies Vaccine for Humans market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Rabies Vaccine for Humans market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Rabies Vaccine for Hu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs